Literature DB >> 12757168

TIPS for management of refractory ascites: response and survival are both unpredictable.

Paul J Thuluvath1, Jasdeep S Bal, Sally Mitchell, Gunnar Lund, Anthony Venbrux.   

Abstract

Refractory ascites is a serious complication of advanced cirrhosis with a 1-year transplant-free survival of 20-50%. The aim of our study was to investigate the short- and long-term effects of transjugular intrahepatic portosystemic shunt (TIPS) in the management of refractory ascites. In all 65 patients (39 M, 26 F; Child B 55%, Child C 45%, mean MELD score 14.8 +/- 6.6) with liver disease (alcoholic 40%, cryptogenic 20%, HCV 14%, others 26%) and refractory ascites were included in this study. Forty-eight (74%) patients had no signs of hepatic encephalopathy (HE), 16 (24%) had mild and 1 (2%) had moderate HE before TIPS; 28 (43%) had mild (> 1.2 and < 2.4 mg/dl) and 6 patients (9%) had moderate (> 2.4 mg/dl) renal dysfunction. Mean follow-up was 55.5 +/- 70.2 weeks. Treatment success, defined as complete response, partial response, and no response, and survival was determined at 3 weeks, and 3, 6, 12, 24, and 36 months after TIPS. TIPS was successful in all patients. Mean portal venous pressure gradient improved significantly after TIPS (24 +/- 8 to 10 +/- 4). During follow-up, 40 (58%) patients died and 17 (27%) patients had liver transplantation (OLT); 20 (31%) patients had 38 shunt revisions due to lack of initial response or recurrence of ascites. The response was assessed in patients who were alive, without OLT, at each time point. Complete response was seen in 10%, 23%, 17%, 11%, 22% and 33%; partial response was seen in 46%, 46%, 40%, 44%, 28%, and 8%; and no response was seen in 44%, 31%, 43%, 41 %, 39%, and 50% at 3 weeks, and 3, 6, 12, 24, and 36 months respectively. There were no pre-TIPS variables that could predict the response at 3 weeks, 3 months, or 6 months. Mild HE was seen in 8 (12%) patients and severe HE was seen in 16 (25%) immediately after TIPS. The mortality at 3 weeks, and 3, 6, 12, 24, and 36 months was 26%, 38%, 46%, 51%, 57%, and 58%, respectively. Three-week (P = 0.01) and 3-month (P = 0.04) mortality was higher in Child C patients compared to Child B. However, there were no independent predictors of survival on multivariate analysis at 3 or 6 months. Child-Pugh score 3 weeks after TIPS was a strong predictor of mortality. In conclusion, in patients with refractory ascites, TIPS was associated with a high mortality and morbidity. The response and the mortality were both unpredictable on the basis of pretransplant variables.

Entities:  

Mesh:

Year:  2003        PMID: 12757168     DOI: 10.1023/a:1022544917898

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  44 in total

1.  Transjugular intrahepatic portosystemic shunt compared with endoscopic treatment for prevention of variceal rebleeding: A meta-analysis.

Authors:  G V Papatheodoridis; J Goulis; G Leandro; D Patch; A K Burroughs
Journal:  Hepatology       Date:  1999-09       Impact factor: 17.425

2.  A randomised prospective trial comparing daily paracentesis and intravenous albumin with recirculation in diuretic refractory ascites.

Authors:  H L Smart; D R Triger
Journal:  J Hepatol       Date:  1990-03       Impact factor: 25.083

Review 3.  TIPS and hepatic encephalopathy.

Authors:  G Pomier-Layrargues
Journal:  Semin Liver Dis       Date:  1996-08       Impact factor: 6.115

4.  Transjugular intrahepatic portal-systemic shunt in the treatment of refractory ascites: effect on clinical, renal, humoral, and hemodynamic parameters.

Authors:  J Quiroga; B Sangro; M Núñez; I Bilbao; J Longo; L García-Villarreal; J M Zozaya; M Betés; J I Herrero; J Prieto
Journal:  Hepatology       Date:  1995-04       Impact factor: 17.425

5.  Renal effects of transjugular intrahepatic portosystemic shunt in cirrhosis: comparison of patients with ascites, with refractory ascites, or without ascites.

Authors:  A L Gerbes; V Gülberg; T Waggershauser; J Holl; M Reiser
Journal:  Hepatology       Date:  1998-09       Impact factor: 17.425

6.  Treatment of refractory ascites using transjugular intrahepatic portosystemic shunt (TIPS): a caution.

Authors:  J P Martinet; D Fenyves; L Legault; L Roy; M P Dufresne; L Spahr; M Lafortune; G Pomier-Layrargues
Journal:  Dig Dis Sci       Date:  1997-01       Impact factor: 3.199

7.  The transjugular intrahepatic portosystemic stent-shunt procedure for refractory ascites.

Authors:  A Ochs; M Rössle; K Haag; K H Hauenstein; P Deibert; V Siegerstetter; M Huonker; M Langer; H E Blum
Journal:  N Engl J Med       Date:  1995-05-04       Impact factor: 91.245

8.  Portosystemic hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with cirrhosis: clinical, laboratory, psychometric, and electroencephalographic investigations.

Authors:  W Nolte; J Wiltfang; C Schindler; H Münke; K Unterberg; U Zumhasch; H R Figulla; G Werner; H Hartmann; G Ramadori
Journal:  Hepatology       Date:  1998-11       Impact factor: 17.425

9.  Portosystemic encephalopathy after transjugular intrahepatic portosystemic shunt: results of a prospective controlled study.

Authors:  A J Sanyal; A M Freedman; M L Shiffman; P P Purdum; V A Luketic; A K Cheatham
Journal:  Hepatology       Date:  1994-07       Impact factor: 17.425

10.  Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomized study.

Authors:  P Ginés; V Arroyo; E Quintero; R Planas; F Bory; J Cabrera; A Rimola; J Viver; J Camps; W Jiménez
Journal:  Gastroenterology       Date:  1987-08       Impact factor: 22.682

View more
  9 in total

1.  TIPS versus peritoneovenous shunt in the treatment of medically intractable ascites: a prospective randomized trial.

Authors:  Alexander S Rosemurgy; Emmanuel E Zervos; Whalen C Clark; Donald P Thometz; Thomas J Black; Bruce R Zwiebel; Bruce T Kudryk; L Shane Grundy; Larry C Carey
Journal:  Ann Surg       Date:  2004-06       Impact factor: 12.969

2.  Synergism between hepatocellular injury and shunting in portosystemic encephalopathy (PSE): case report of acute brittle TIPS-induced PSE.

Authors:  Gil Weitzman; Neil J Schamberg; Gerond Lake-Bakaar
Journal:  Dig Dis Sci       Date:  2007-07-20       Impact factor: 3.199

3.  In vivo validation of 4D flow MRI for assessing the hemodynamics of portal hypertension.

Authors:  Alejandro Roldán-Alzate; Alex Frydrychowicz; Eric Niespodzany; Ben R Landgraf; Kevin M Johnson; Oliver Wieben; Scott B Reeder
Journal:  J Magn Reson Imaging       Date:  2012-11-12       Impact factor: 4.813

4.  Transjugular intrahepatic portosystemic shunt for the treatment of medically refractory ascites.

Authors:  Ahmad Parvinian; James T Bui; M Grace Knuttinen; Jeet Minocha; Ron C Gaba
Journal:  Diagn Interv Radiol       Date:  2014 Jan-Feb       Impact factor: 2.630

5.  Transjugular Intrahepatic Porto-Systemic Shunt in Patients with Liver Cirrhosis and Model for End-Stage Liver Disease ≥15.

Authors:  Mona Ascha; Mohamad Hanouneh; Mustafa S Ascha; Nizar N Zein; Mark Sands; Rocio Lopez; Ibrahim A Hanouneh
Journal:  Dig Dis Sci       Date:  2016-05-06       Impact factor: 3.199

6.  Fifteen years' experience with transjugular intrahepatic portosystemic shunt (TIPS) using bare stents: retrospective review of clinical and technical aspects.

Authors:  C Gazzera; D Righi; F Valle; A Ottobrelli; M Grosso; G Gandini
Journal:  Radiol Med       Date:  2008-12-11       Impact factor: 3.469

7.  Improving survival in decompensated cirrhosis.

Authors:  Amar Nath Mukerji; Vishal Patel; Ashokkumar Jain
Journal:  Int J Hepatol       Date:  2012-07-02

8.  Outcomes After Transjugular Intrahepatic Portosystemic Shunt in Cirrhotic Patients 70 Years and Older.

Authors:  Natasha Adlakha; Mark W Russo
Journal:  J Clin Med       Date:  2020-01-31       Impact factor: 4.241

Review 9.  Hepatic hydrothorax: An update and review of the literature.

Authors:  Dmitry Victorovich Garbuzenko; Nikolay Olegovich Arefyev
Journal:  World J Hepatol       Date:  2017-11-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.